After conducting a head-to-head comparison with competing instruments, clinicians selected the Abbott iStat instrument to monitor blood clotting during surgical interventions.
GenMark Diagnostics received clearance for a third BCID panel that the firm said paves the way for a customizable approach to sepsis MDx.
Abbott's test is designed to detect two proteins — GFAP and UCH-L1 — that are released from the brain into the bloodstream following brain injury.
Within the diagnostics business, Abbott's core laboratory sales grew 4 percent but its other diagnostic segments were down year over year.
The Austin, Texas-based company offers more than 30 tests, including those for food sensitivity, fertility and women's hormones, sexually transmitted diseases, and thyroid.
The test can be used to rapidly and accurately identify patients suffering from heart attacks, and to help identify low-risk patients who may be safely discharged, the firm said.
The firm said that its Vitros XT MicroSlides improve lab turnaround time by delivering simultaneous results for pairs of tests that physicians frequently order.
Designed for small and medium-sized labs, the system offers automated blood typing and screening based on gel card technology with minimum user intervention.
The firm has expansive plans, including a possible launch of 40 different types of tests. It currently plans to launch a liver function test in the US this summer.
Under the deal, Theradiag will have access to Immunodiagnostic's IDS-i10 automation system, and Immunodiagnostic will distribute Theradiag tests in 33 countries.
Roche alleged that lower-priced test strips intended for sale via mail order were redirected for sale at higher prices through retail pharmacies.
The companies today launched four assays for the Chinese market for renal, liver, and cardiac testing for use on the Vitros 4600 and Vitros 5600 systems.
The Optigen AP 3600 can process up to 100 panels, or as many as 3,600 individual allergen results, in one day, and allows for true walk-away time, the firm said.
The Vitros XT MicroSlide technology allows labs to run two tests that are commonly ordered together simultaneously from a single blood sample.
IL said that the rapid basic metabolic panel is designed for testing at the point of care, primarily in hospital emergency departments and clinical laboratories.
The Army previously awarded Abbott $11.3 million to develop a TBI test. Abbott has worked with DoD since 2014 to develop tests to help evaluate potential concussions.
The company plans to partner with manufacturers to bring different POC assay cartridges onto its reader instrument.
The platform enables the assessment of hemoglobin levels at the point of care and quantitatively measures hemoglobin in capillary or venous whole blood.
The firm's CTO Sarah Levy said the Series C funding will enable it to expand R&D activities to develop applications beyond complete blood counts.
The company aims to launch the test, which it believes will improve monitoring and treatment of patients with diabetes, in China within the next two years.